Endothelial estrogen receptor-α plays a crucial role in the atheroprotective action of 17β-estradiol in low-density lipoprotein receptor-deficient mice

Circulation

Volumn 120, Issue 25, 2009, Pages 2567-2576

  Billon Galés, Audrey ^a   Fontaine, Coralie ^a   Douin Echinard, Victorine ^a   Delpy, Laurent ^a,b   Berges, Hortense ^a   Calippe, Bertrand ^a   Lenfant, Françoise ^a   Laurell, Henrik ^a   Guéry, Jean Charles ^a   Gourdy, Pierre ^a   Arnal, Jean François ^a  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

Atherosclerosis; Endothelium; Estrogens; Hormones; Receptors

Indexed keywords

ANGIOPOIETIN RECEPTOR; CRE RECOMBINASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; INTEGRASE; PROTEIN TYROSINE KINASE; TEK PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROMA; CELL LINEAGE; CHIMERA; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; ENDOTHELIUM CELL; EVALUATION; FEMALE; HEMATOPOIETIC CELL; HORMONE ACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; GENETICS; METABOLISM; MOUSE MUTANT; OVARIECTOMY; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; INTEGRASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OVARIECTOMY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, LDL;

EID: 73949135461     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.898445     Document Type: Article

References (46)

1. Arnal JF, Scarabin PY, Tremollieres F, Laurell H, Gourdy P. Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol. 2007;18:554-560.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
4. Vita JA, Keaney JF Jr. Hormone replacement therapy and endothelial function: the exception that proves the rule? Arterioscler Thromb Vasc Biol. 2001;21:1867-1869.
5. Clarkson TB, Appt SE. Controversies about HRT: lessons from monkey models. Maturitas. 2005;51:64-74.
6. Rosenfeld ME, Kauser K, Martin-McNulty B, Polinsky P, Schwartz SM, Rubanyi GM. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis. 2002;164:251-259.
7. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, Arnal JF. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002;90:413-419.
8. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation. 2001; 103:423-428.
9. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res. 2002;90:1087-1092.
10. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 1993;90:11162-11166.
11. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's athero-protective effects on lesion size in Apoe\-/\-mice. J Clin Invest. 2001; 107:333-340.
12. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development. 2000;127:4277-4291.
13. Elhage R, Arnal JF, Pierragi M-T, Duverger N, Fiévet C, Faye JC, Bayard F. Estradiol-17/3 prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1997;17:2679-2684.
14. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: a time course study in cholesterol-clamped rabbits. Circulation. 1999;100:1727-1733.
15. Marsh MM, Walker VR, Curtiss LK, Banka CL. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. J Lipid Res. 1999;40:893-900.
16. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802-815.
17. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
18. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-574.
19. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apopto-sis: estradiol as a survival factor. Circulation. 1997;95:1505-1514.
20. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21:6-12.
21. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation. 1997;95:1768-1772.
22. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med. 2001;193:741-754.
23. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, Gourdy P, Lenfant F, Laurell H, Krust A, Chambon P, Arnal JF. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci USA. 2009;106:2053-2058.
24. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS, Bayard F, Arnal JF. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc Natl Acad Sci USA. 2002;99:2205-2210.
25. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 1996;93:10022-10027.
26. Calippe B, Douin-Echinard V, Laffargue M, Laurell H, Rana-Poussine V, Pipy B, Guery JC, Bayard F, Arnal JF, Gourdy P. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. J Immunol. 2008;180:7980-7988.
27. Yao L, Yokota T, Xia L, Kincade PW, McEver RP. Bone marrow dysfunction in mice lacking the cytokine receptor gp130 in endothelial cells. Blood. 2005;106:4093-4101.
28. Takakura N, Huang XL, Naruse T, Hamaguchi I, Dumont DJ, Yanco-poulos GD, Suda T. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998;9:677-686.
29. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis. 2001;30:36-44.
30. Holm P, Korsgaard N, Shalmi M, Andersen HL, Hougaard P, Skouby SO, Stender S. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J Clin Invest. 1997;100:821-828.
31. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, Imes S, Fishbein MC, Clinton SK, Libby P, Lusis AJ, Rajavashisth TB. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol. 1997;150:1687-1699.
32. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA. 1995;92:8264-8268.
33. Gautier EL, Huby T, Saint-Charles F, Ouzilleau B, Pirault J, Deswaerte V, Ginhoux F, Miller ER, Witztum JL, Chapman MJ, Lesnik P. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation. 2009;119:2367-2375.
34. Elhage R, Bayard F, Richard V, Holvoet P, Duverger N, Fievet C, Arnal JF. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation. 1997;96:3048-3052.
35. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, Fitzgerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-1957.
36. Nathan L, Pervin S, Singh R, Rosenfeld M, Chaudhuri G. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis. Circ Res. 1999;85:377-385.
37. Gourdy P, Mallat Z, Castano C, Garmy-Susini B, Mac Gregor JL, Tedgui A, Arnal JF, Bayard F. The atheroprotective effect of 17beta-estradiol is not altered in P-selectin-or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis. 2003;166:41-48.
38. Gardner G, Banka CL, Roberts KA, Mullick AE, Rutledge JC. Modified LDL-mediated increases in endothelial layer permeability are attenuated with 17 beta-estradiol. Arterioscler Thromb Vasc Biol. 1999;19:854-861.
39. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apopto-sis: estradiol as a survival factor. Circulation. 1997;95:1505-1514.
40. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.
41. Elhage R, Clamens S, Reardon-Alulis C, Getz GS, Fievet C, Maret A, Arnal JF, Bayard F. Loss of atheroprotective effect of estradiol in immu-nodeficient mice. Endocrinology. 2000;141:462-465.
42. Elhage R, Gourdy P, Huc X, Brouchet L, Castano C, Barreira Y, Cou-loumiers JC, Fievet C, Hansson G, Arnal JF, Bayard F. The atheropro-tective effect of 17beta-estradiol depends on complex interactions in adaptive immunity. Am J Pathol. 2005;167:267-274.
43. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endo-thelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108:3115-3121.
44. Toutain CE, Filipe C, Billon A, Fontaine C, Brouchet L, Guery JC, Gourdy P, Arnal JF, Lenfant F. Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler Thromb Vasc Biol. 2009;29:1543-1550.
45. Jordan VC. The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci. 2001;949:72-79.
46. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine defining the "S" in SERMs. Science. 2002;295:2380-2381.